Des-gamma-carboxy prothrombin is a promising biomarker of hepatocellular carcinoma and a predictor of complications in patients with chronic liver diseases

作     者：Lan-Yue Pan Xiao-Meng Hu Peng Han Dao-Feng Yang Lan-Yue Pan;Xiao-Meng Hu;Peng Han;Dao-Feng Yang

作者机构：Department and Institute of Infectious DiseasesTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Tuberculosis Ⅳ WardWuhan Pulmonary HospitalWuhan 430030China Department of Thoracic SurgeryTongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2023年第22卷第2期

页      面：200-204页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：prothrombin hepatocellular diagnosis 

摘      要：To the Editor: Although des-gamma-carboxy prothrombin(DCP) is considered a complementary biomarker to alpha-fetoprotein(AFP) in the diagnosis of hepatocellular carcinoma(HCC), its cut-off value has not been recommended in any guideline. This study aimed to explore the diagnostic efficacy of DCP on HCC.